Inmune Bio, Inc. (INMB) — SEC Filings
Inmune Bio, Inc. (INMB) — 50 SEC filings. Latest: 8-K (Dec 23, 2025). Includes 41 8-K, 3 10-Q, 2 DEF 14A.
View Inmune Bio, Inc. on SEC EDGAR
Overview
Inmune Bio, Inc. (INMB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: On December 22, 2025, Inmune Bio, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and exhibits. The company, incorporated in Nevada, is involved in biological products.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant filing sentiment for Inmune Bio, Inc. is neutral.
Filing Type Overview
Inmune Bio, Inc. (INMB) has filed 41 8-K, 3 10-Q, 2 DEF 14A, 1 DEFA14A, 1 10-K, 1 SC 13G, 1 SC 13G/A with the SEC between Sep 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of INMB's 40 recent filings, 2 were flagged as high-risk, 16 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $50 thousand |
| Net Income | -$40.669 million |
| EPS | -$1.68 |
| Debt-to-Equity | 0.31 |
| Cash Position | $27.734 million |
| Operating Margin | -N/A |
| Total Assets | $33.358 million |
| Total Debt | $7.980 million |
Key Executives
- David Moss
- June 30, 2025
- August 7, 2025
- Dr. David M. Reifman
- Dr. David M. Siegel
Industry Context
INmune Bio operates in the highly competitive clinical-stage biotechnology sector, focusing on inflammation and immunology-driven diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovative therapies and navigating complex clinical trials, with companies often relying on external funding to advance their pipelines.
Top Tags
filing (11) · sec-filing (10) · 8-k (9) · 8-K (8) · financials (7) · material-agreement (5) · exhibits (5) · corporate-governance (4) · Biotechnology (3) · biotech (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-38793 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 47-5205835 | Company's tax identification number. |
| Net Loss | $40.669M | for the nine months ended September 30, 2025, increased from $32.864M in 2024 |
| Impairment of acquired in-process R&D intangible assets | $16.514M | due to XPro's Phase 2 failure |
| Net cash used in operating activities | $19.6M | for the nine months ended September 30, 2025 |
| Cash and cash equivalents | $27.734M | as of September 30, 2025, up from $20.922M at Dec 31, 2024 |
| Net proceeds from sale of common stock and warrants | $27.544M | for the nine months ended September 30, 2025 |
| Research and development expenses | $18.330M | for the nine months ended September 30, 2025, down from $25.813M in 2024 |
| Common shares outstanding | 26,585,258 | as of October 30, 2025 |
| Net loss per common share | $0.24 | for the three months ended September 30, 2025 |
| Shares Outstanding | 26,585,258 | As of the September 30, 2025 record date, each share is entitled to one vote. |
| Special Meeting Date | November 18, 2025 | Date when stockholders will vote on the option repricing and adjournment proposals. |
| Record Date | September 30, 2025 | Date by which stockholders must own shares to vote at the Special Meeting. |
| Revenue | 0 | Consistent with a clinical-stage biotech, indicating no product sales. |
| Increase in Net Loss | 14.1% | From Q2 2024 to Q2 2025, highlighting rising operational costs. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Inmune Bio, Inc. (INMB)?
Inmune Bio, Inc. has 50 recent SEC filings from Sep 2024 to Dec 2025, including 41 8-K, 3 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of INMB filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 47 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Inmune Bio, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Inmune Bio, Inc. (INMB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Inmune Bio, Inc.?
Key financial highlights from Inmune Bio, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for INMB?
The investment thesis for INMB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Inmune Bio, Inc.?
Key executives identified across Inmune Bio, Inc.'s filings include David Moss, June 30, 2025, August 7, 2025, Dr. David M. Reifman, Dr. David M. Siegel.
What are the main risk factors for Inmune Bio, Inc. stock?
Of INMB's 40 assessed filings, 2 were flagged high-risk, 16 medium-risk, and 22 low-risk.
What are recent predictions and forward guidance from Inmune Bio, Inc.?
Forward guidance and predictions for Inmune Bio, Inc. are extracted from SEC filings as they are enriched.